We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Researchers Identify Two Proteins Required to Reverse Senescence

By LabMedica International staff writers
Posted on 21 Aug 2018
Print article
Image: A micrograph showing cellular senescence in human cells (Photo courtesy of Eva Latorre, University of Exeter).
Image: A micrograph showing cellular senescence in human cells (Photo courtesy of Eva Latorre, University of Exeter).
Two protein-splicing factors have been identified that enable mitochondria-targeted hydrogen sulfide to reverse senescence in endothelial cells.

Senescent cells are aged or damaged cells that no longer are able to perform their normal roles. These cells interfere with the functioning of the tissue in which they accumulate, and eliminating them is considered to be a promising therapeutic approach. Hydrogen sulfide (H2S) has been found to alleviate senescence, but the pathways by which it accomplishes this are unclear.

To study these pathways, investigators at the University of Exeter (United Kingdom) assessed the effect of the H2S donor Na-GYY4137, and since mitochondria are a source and a target of H2S, three novel H2S donors, AP39, AP123, and RT01 previously demonstrated to be targeted specifically to the mitochondria, on splicing regulatory factor expression and cell senescence phenotypes in senescent primary human endothelial cells.

The investigators reported in the July 19, 2018, online edition of the journal Aging that H2S donors targeted to the mitochondria reversed senescence, but each demonstrated a very specific upregulation of transcripts encoding the splicing activator protein SRSF2 (Splicing factor, arginine/serine-rich 2) and the splicing inhibitor protein HNRNPD (Heterogeneous nuclear ribonucleoprotein D0). Abolition of either SRSF2 or HNRNPD expression in primary endothelial cells in the absence of any other treatment resulted in increased levels of cellular senescence. None of the H2S donors were able to reduce senescent cell load in cells in which SRSF2 or HNRNPD expression had been abrogated.

These results indicated that mitochondria-targeted H2S was capable of rescuing senescence phenotypes in endothelial cells through mechanisms that specifically involved SRSF2 and HNRNPD.

"As human bodies age, they accumulate old (senescent) cells that do not function as well as younger cells," said senior author Dr. Lorna Harries, associate professor of molecular genetics at the University of Exeter. "This is not just an effect of ageing – it is a reason why we age. We used to think age-related diseases like cancer, dementia, and diabetes each had a unique cause, but they actually track back to one or two common mechanisms. This research focuses on one of these mechanisms, and the findings with our compounds have potentially opened up the way for new therapeutic approaches in the future."

Related Links:
University of Exeter

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
Benchtop Cooler
PCR-Cooler & PCR-Rack

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.